HOUSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, is pleased to announce the successful completion of its Initial Public Offering (IPO). Notable is that over 30% of the IPO was purchased by existing investors which further demonstrates strong belief in the company and its potential.
Frank D. Heuszel, CEO of Impact BioMedical, commented, "The significant ...